FILING ANALYSIS · MONDAY, NOVEMBER 16
Astrazeneca AZN — RNS: Klygefa Gefurulimab Approved In The Us
positive
Astrazeneca's Klygefa (gefurulimab) has received FDA approval for adult anti-AChR+ generalized myasthenia gravis, a significant regulatory milestone for the company.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →